Search Results

Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.

Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals.

MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled “In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus.”

MicuRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Qualified Infectious Disease Product and the Fast Track Designation under the Generating Antibiotic Incentives Now Act for contezolid tablet and contezolid acefosamil tablet and intravenous as novel new oxazolidinone antibiotics for the treatment of moderate to severe diabetic foot infection without concomitant osteomyelitis.

Shanghai MicuRx Pharmaceutical Co., Ltd. announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc.

Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.